Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Public ClinicalTrials.gov record NCT06838000. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents
Study identification
- NCT ID
- NCT06838000
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Enrollment
- 1,268 participants
Conditions and interventions
Conditions
Interventions
- PCV21 Biological
- 20vPCV Biological
Biological
Eligibility (public fields only)
- Age range
- 7 Months to 17 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2025
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Oct 5, 2025
2025 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site # 8400008 | Paramount | California | 90723 | — |
| Site # 8400024 | Doral | Florida | 33166 | — |
| Site # 8400007 | Hialeah | Florida | 33012 | — |
| Site # 8400014 | Melbourne | Florida | 32934 | — |
| Site # 8400009 | Miami | Florida | 33166 | — |
| Site # 8400016 | Miami | Florida | 33166 | — |
| Site # 8400021 | Fayetteville | Georgia | 30214 | — |
| Site # 8400004 | Union City | Georgia | 30291 | — |
| Site # 8400003 | Sioux City | Iowa | 51106 | — |
| Site # 8400023 | Erlanger | Kentucky | 41018 | — |
| Site # 8400018 | Biloxi | Mississippi | 39531 | — |
| Site # 8400012 | Ridgeland | Mississippi | 39531 | — |
| Site # 8400002 | Omaha | Nebraska | 68114 | — |
| Site #8400010 | Binghamton | New York | 13905 | — |
| Site # 8400025 | Rochester | New York | 14642 | — |
| Site # 8400001 | Houston | Texas | 77065 | — |
| Site # 8400017 | Stephenville | Texas | 76401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06838000, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06838000 live on ClinicalTrials.gov.